Expert Commentary: Practice-Changing Advances in Type 2 Diabetes

Learn expert perspectives on pivotal studies of SGLT2 inhibitors in type 2 diabetes including possible renal protection in those with or without established chronic kidney disease.

Share

Program Content

Activities

Renal Protection in T2D
Why I Recommend SGLT2 Inhibitors for Renal Protection in Patients With T2D
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2021

Expires: June 20, 2022

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Merck